What this pack is
Mestinon is the brand name in this record; pyridostigmine is the generic name. Read both together with the dosage form (multiple oral forms (tablets and oral liquid)).
PACK CHECK · MARKET FIRST
MestinonGeneric namepyridostigmine
How this medicine works
The DailyMed label describes pyridostigmine as an orally active cholinesterase inhibitor that inhibits acetylcholine breakdown and helps nerve-impulse transmission. This explains a labelled pharmacologic pathway; it does not determine anyone's symptom cause, product choice, tablet count, oral-solution millilitres, combination or adjustment plan.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Mestinon
- Generic name
- pyridostigmine
- Dosage-form class
- Oral solution, immediate-release tablets and extended-release tablets: a shared brand or generic name does not establish self-conversion, substitution or splitting (as listed in the U.S. public label)
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
The 60 mg immediate-release tablet, 180 mg TIMESPAN extended-release tablet and 60 mg/5 mL oral solution are three labelled product identities. Their package numbers are not an interchangeable arithmetic or a self-conversion between forms.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
3 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v20 (published 2 February 2023)
60 mg per tablet; 100-tablet bottle
- Product code
- NDC 0187-3010-30
- Form and route
- pyridostigmine bromide immediate-release oral tablet · oral
- pyridostigmine bromide
- 60 mglabelled amount per tablet
- Package
- 100 tablets per bottle
- Labelled appearance
- white · round tablet · imprint MESTINON / V / 60Scored in this labelled presentation
United States label · DailyMed SPL v20 (published 2 February 2023)
180 mg per tablet; 30-tablet bottle (TIMESPAN extended-release tablet)
- Product code
- NDC 0187-3013-30
- Form and route
- MESTINON TIMESPAN extended-release oral tablet · oral
- pyridostigmine bromide
- 180 mglabelled amount per tablet
- Package
- 30 tablets per bottle
- Labelled appearance
- light straw yellow · oval capsule-shaped tablet · imprint MES / V / 180Unscored in this labelled presentation
United States label · DailyMed SPL v20 (published 2 February 2023)
60 mg per 5 mL; 473 mL bottle
- Product code
- NDC 0187-3012-20
- Form and route
- pyridostigmine bromide oral solution · oral
- Container
- bottle · 473 mL
- pyridostigmine bromide
- 60 mglabelled amount per 5 mL
- Package
- 1 bottle per package
- Labelled appearance
- liquid formulation; check the exact label and measuring device ·
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
MESTINON label reading: 60 mg tablets, 180 mg TIMESPAN and 60 mg/5 mL oral solution must be checked separately
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the U.S. DailyMed public label to check MESTINON, pyridostigmine bromide, the exact form, labelled amount per unit, NDC and pack. It does not provide anyone's tablet count, oral-solution millilitres, interval, missed-use action, combination, switching or stopping plan.
- The 60 mg immediate-release tablet, 180 mg TIMESPAN extended-release tablet and oral solution containing 60 mg per 5 mL are separately listed product identities. A shared brand or generic name does not make them self-convertible, make-up interchangeable, combinable or substitutable by milligrams, tablets or millilitres.
- The 60 mg immediate-release tablet is described as quadrisect scored and the 180 mg TIMESPAN tablet as unscored. These are appearance-check fields, not permission from this webpage for anyone to split, crush, repackage or proportionally reduce a tablet. Handling the exact tablet must follow the current label, prescription and pharmacist/prescribing-team advice.
- Oral-solution wording of “60 mg/5 mL” is a concentration identity field, not a formula for changing tablets into household-spoon or personal millilitre amounts. Check the exact product, label, supplied measuring device and prescribing information together; this page does not generate a conversion or measuring instruction.
- The label notes that signs of too much or too little may be difficult to distinguish and addresses urgent risks including severe weakness, breathing/swallowing difficulty, marked secretions or serious gastrointestinal symptoms. With an acute, serious or progressive concern, prioritise local urgent medical support; do not self-increase, make up, pause or change product from this page.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. MESTINON pyridostigmine bromide public label (Bausch Health; SPL v20) ↗reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Mestinon (pyridostigmine). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Mestinon is the brand in this record and pyridostigmine is the active-ingredient name. Check both with the dosage form (Oral solution, immediate-release tablets and extended-release tablets: a shared brand or generic name does not establish self-conversion, substitution or splitting (as listed in the U.S. public label)) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How pyridostigmine works: the label describes cholinesterase inhibition, not a basis for personal adjustment
- “Cholinesterase inhibition” is not a self-diagnosis for weakness, fatigue, eyelid, swallowing, breathing or gastrointestinal symptoms, and cannot replace professional judgement based on the exact product, condition and clinical information.
- A shared mechanism, similar generic name or oral route does not make MESTINON liquid, immediate-release tablets, extended-release tablets or another neuromuscular medicine self-combinable, alternatable, milligram-convertible or substitutable. The complete medicine list and current labels require joint review.
- A mechanism page cannot manage sudden or worsening weakness, breathing/swallowing difficulty, fainting, severe secretions or another acute concern. With these problems, prioritise local urgent medical support rather than experimenting with forms or adjusting from package numbers.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. MESTINON pyridostigmine bromide public label (Bausch Health; SPL v20) ↗reviewed 2026-08-20
- FDA Drugs@FDA official search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Mestinonpyridostigmine
This page links to public primary-source material for Mestinon. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Historical marketing-record node for the 60 mg tablet
The current DailyMed label lists NDA 009829 and a 1955 marketing-start node for the 60 mg tablet. This page treats it as a historical product-record entry in the U.S. public label, not as evidence for another market.
DailyMed: current U.S. MESTINON public label (SPL v20) ↗Historical marketing-record node for 180 mg TIMESPAN
The current DailyMed label lists NDA 011665 and a 1959 marketing-start node for 180 mg TIMESPAN. Its extended-release property must be checked separately from the 60 mg immediate-release tablet and oral solution.
DailyMed: current U.S. MESTINON public label (SPL v20) ↗Historical marketing-record node for the oral solution
The current DailyMed label lists NDA 015193 and a 1965 marketing-start node for the oral solution. 60 mg/5 mL is a liquid-product identity field, not a conversion instruction.
DailyMed: current U.S. MESTINON public label (SPL v20) ↗Current SPL v20 published on DailyMed
DailyMed lists 2 February 2023 as the publication date for the current MESTINON SPL v20. This page uses it as source-version information, not as evidence of availability or an individual-use conclusion.
DailyMed: current U.S. MESTINON public label (SPL v20) ↗
MARKET SCOPE
Market-record boundary
United States
Current label and three exact package identities linkedThis page separately lists the 60 mg immediate-release tablet, 180 mg TIMESPAN extended-release tablet and 60 mg/5 mL oral solution; it does not establish actual availability, stock, individual use or self-directed interchangeability.
Mainland China, EU, Japan and other markets
Market record not establishedNo local trade name, approval, strength, pack, supply, originator relationship or interchangeability is inferred from the U.S. public label.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Can 60 mg, 180 mg TIMESPAN and 60 mg/5 mL be exchanged from milligrams alone?
No. They identify different product forms: an immediate-release tablet, extended-release tablet and oral solution. The complete brand, form, labelled amount, NDC, label version and prescription need joint review by a pharmacist or prescribing team.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.